ABSTRACT
There has been a great deal of advancement in the ›eld of nanotechnology and its application to ocular diseases. Nanotechnology refers to the use of particles or molecules that are on the nanometer scale, generally with at least one dimension under 100 nm (Nguyen et al. 2010). Due to their small size, nanoparticles have immense potential as vehicles for gene therapy and drug delivery, along with a plethora of other applications in the biomedical ›eld, such as diagnostics and bioimaging (Cai et al. 2008; Foy et al. 2010; Powell et al. 2010). Cutting-edge work with nanotechnology has shown promise for the treatment of multiple diseases, including ocular diseases such as retinal degeneration and glaucoma (Chen et al. 2006; Zarbin et al. 2010).
